ArticleAmerican journal of cardiovascular drugs : drugs, devices, and other interventions2026
Risk of Hematuria, Proteinuria, and Cardiovascular Events in Patients Treated with Rosuvastatin Compared with Atorvastatin: A Retrospective Cohort Study in 136,680 Patients.
Article in American journal of cardiovascular drugs : drugs, devices, and other interventions, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundRosuvastatin and atorvastatin are the two primary high-intensity statins used for cardiovascular risk reduction. However, concerns have been raised regarding the renal safety profile of rosuvastatin. This study compared risks of hematuria, proteinuria, and cardiovascular events between rosuvastatin- and atorvastatin-treated patients.
methodsThis is a retrospective cohort study of atorvastatin and rosuvastatin users from 1 January 2018 to 31 December 2021. Inverse probability of treatment weighting was used to mitigate confounding. Poisson regression models were used to estimate adjusted relative risks.
resultsOf 136,680 patients (median age 61 years, 42.6% female), 46,292 were treated with atorvastatin and 90,388 rosuvastatin. During follow-up, there were 619 cases of proteinuria, 1843 cases of hematuria, and 19 cases of end-stage renal disease. Compared with atorvastatin, rosuvastatin was associated with a nonsignificant increase in the risk of hematuria (adjusted risk ratio [aRR] 1.1, 95% confidence interval [CI] 0.98-1.24) and proteinuria (aRR 1.02, 95% CI 0.83-1.25). Risk of cardiovascular events was significantly lower with rosuvastatin (aRR 0.77, 95% CI 0.70-0.83). Rosuvastatin was associated with a lower risk of myocardial infarction (aRR 0.75, 95% CI 0.63-0.91) and stroke (aRR 0.76, 95% CI 0.62-0.94) but not heart failure (aRR 0.82, 95% CI 0.63-1.06). Significant cardiovascular risk reduction was observed with rosuvastatin in the first 6 months. CONCLUSIONS AND RELEVANCE: Compared with atorvastatin, rosuvastatin was associated with a significantly lower risk of cardiovascular events and a nonsignificant increase in hematuria and proteinuria. Overall, the cardiovascular benefits of rosuvastatin appear to outweigh the minor renal risks.
Indexed as
Identifiers
41182640What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.